Poseida Therapeutics, Inc. Deferred Revenue
Poseida Therapeutics, Inc. had Deferred Revenue of $37.27 million as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2024-11-07
- 2024-09-30: Deferred Revenue, Current $37.27M.
- 2024-06-30: Deferred Revenue, Current $63.29M.
- 2024-03-31: Deferred Revenue, Current $49.77M.
- 2023-12-31: Deferred Revenue, Current $31.01M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2024-09-30 | $37.27M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $63.29M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $49.77M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $31.01M 10-Q · filed 2024-11-07 |
| 2023-09-30 | $44.81M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $20.23M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $20.09M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $19.72M 10-K · filed 2024-03-07 |
| 2022-09-30 | $16.73M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $1.05M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $3.36M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $4.50M 10-K · filed 2023-03-09 |